Featuring prostate Health

Quick facts about the powerful prostate health supporting ingredients in this product
(Please note disclaimer at bottom of page):

• Saw Palmetto Extract - was used historically both for food and for treatment of urinary and reproductive complaints, and for removing mucous. It is the most often used botanical extract in regarding to prostate health.
  
  About the age of 40, the prostate undergoes a hormone--mediated growth spurt, due to an increase in the testosterone metabolite, dihydrotestosterone (DHT). The enzyme responsible for the production of DHT is found primarily in the cells of the prostate, scrotal skin, testicles and scalp. DHT causes prostatic enlargement as well as male pattern baldness. Saw Palmetto blocks the formation of DHT, inhibits the binding of DHT to prostate cells and blocks the update of DHT into the cell nucleus.
• Phytosterol Extract - a pine tree trunk extract containing beta sitosterols  has been shown to have numerous benefits, including reduction of hair loss (in combination with saw palmetto), reduction of blood cholesterol and reduction of of prostate size.
• Stinging Nettle - is widely used to help alleviate symptoms of reduced urinary flow, incomplete emptying of the bladder, as well as relief of symptoms of arthritis, hay fever and elevated blood sugar.
• Prostate Glandular (Porcine) - one of the newer methods for improving the health of specific glands in the human body is to supplement with desiccated glandulars of those glands from animals. Doing so, provides the exact nutrients that particular gland needs to be healthy.
• Pygeum - numerous human studies report that pygeum significantly reduces urinary hesitancy, urinary frequency, the number of times patients need to wake up at night to urinate, and pain with urination in men who experience mild-to-moderate symptoms.
• Pumpkin Seed - in addition to a large amount of nutrition, pumpkin seed has been shown to reduce inflammatory processes and to interrupt the DHT conversion process that leads to prostate enlargement.
• Uva Ursi (bearberry) - is widely used for bladder and kidney complaints, Uva Ursi is known to increase urine flow.
• Bee Flower Pollen (graminex) is widely used for increased virility and prostate health.

Product Listing Kona Deep Sea Minerals Parasite Cleanse Cleansing Enzymes RiSoTriene Methylate Me Aloe Vera Power Liver Boost Small Molecule Whey Protein SoRelief Cardio Helper Seven Essentials Eight Day Cleanse Stay Young Health Kit Vitamin D Vitamin K2 Probiotics Probiotic Chewables WinkZ Prostate Health C2IT Prostate Health Glycemic Support Coffee Fruit/Berry Supplement Magnascent Iodine

Prostate Health - Nutritionally Supporting the Prostate

A  large percent of men over the age of 40 suffer from an enlarging  prostate gland. This can make urination difficult or increase its frequency.  While initially benign in nature, an enlarged prostate can affect comfort and  quality of life. This comprehensive men’s health focused formulation helps maintain a healthy prostate gland and promote normal urinary function.

Designed to be the most effective prostate health product on the market, our prostate Health product contains an optimum amount of several botanicals and nutrients that have been shown in numerous studies to be effective at supporting the health of the prostate gland.

Prosta Health Ordering Form Item # Description Retail Price Your Price Qty 230 Prosta Health - Bottle of 120 Capsules $28.00 $25.00 123456789 Add to Cart Quantity discounts available: 3 to 5 units: 5%, 6 to 8 units: 10%, 9 plus units: 15%. Money Back Guarantee of Satisfaction on All Products. View Cart

 

Few men ever consider the walnut-sized fibrous gland called the prostate located just below the bladder, until it starts to give them trouble. After the age of 50, the prostate  begins to hypertrophy, or increase in size. This is known as benign  prostatic hypertrophy (BPH). The urethra (the tube that carries urine  from the bladder) runs through the middle of the prostate. Consequently, when the prostate enlarges the urethra is compressed. (Fig. 1) This  causes difficulty in urinating and requires many men to get up three or  four times during the night to urinate. Other symptoms of BPH include  hesitancy, dribbling, reduced force of the urinary stream, and  occasional bleeding or infection. This condition may even proceed to the point of complete urinary obstruction.

Fifty to sixty percent of men between 40-60 years of age suffer from BPH,  escalating to 75 percent of men by age 60 (Fig. 2).1 The projected  annual cost of hospital care and surgical treatment for BPH in the  United States is over $1 billion.

In fact, this condition is so common  that physicians routinely ask their over-50 male patients, not “whether”, but, “How many times do you have to get up at night to go to the  bathroom?”

Causes of Prostatic Enlargement

Prostate hypertrophy and inflammation are believed to be due to the consequences of a number of age-related changes in the metabolism and levels of male steroid hormones.

After the age of fifty, the level of free  testosterone decreases, while levels of prolactin, estradiol, and sex  hormone-binding globulin (SHBG) increase. Concentrations of  dihydrotestosterone (DHT) the active metabolite of testosterone in the  prostate increase, and binding of DHT to prostate tissue increases. DHT  stimulates the prostate cells to enlarge, resulting in the swollen  gland.

5-alpha reductase is the enzyme that converts testosterone  into DHT. Consequently, one approach to preventing BPH has been to use  substances that inhibit this enzyme, thereby blocking the formation of  DHT, and its prostate-enlarging effect. Estrogen also seems to play a  role in BPH by inhibiting the breakdown and removal of testosterone and DHT. The increased ratio of plasma estrogen/testoster-one is due to the  increased formation of estrogens formed by the conversion of  androstenedione to estrone and estradiol by the enzyme, aromatase.  Another approach to preventing or treating BPH is, therefore, to use  aromatase inhibitors to prevent this estrogenic conversion.

Therapeutic Options for BPH

Until recently, outside of “watchful waiting”,€� surgery was about the only  solution for this troublesome condition. Fortunately, less invasive and  more physiological approaches to prevent and treat BPH are now  available, based on our increased understanding of its causes. Clearly, a rational approach should include: (1) normalization of prostate  nutrient levels; (2) restoration of steroid hormones to normal levels;  (3) inhibition of excessive conversion of testosterone to DHT  (dihydrotestosterone); (4) reduction of DHT receptor binding; and (5)  reduction of prostatic inflammatory promoters such as prolactin.

Proscar® is a prescription drug which inhibits 5-alpha reductase. This drug has  recently been introduced into the physician’s toolset for  treatment of BPH. Use of Proscar results in a 20 percent decrease in  prostate size in 50 percent of the men who are treated. Unfortunately,  Proscar is fairly expensive, with the significant side effect of sexual  dysfunction.

Fortunately, however, there are nutritional alternatives  which provide, without adverse effects, equivalent or greater benefits  at reduced cost.

Saw Palmetto (Serenoa repens)

Extracts of saw palmetto berry are being used extensively throughout the world  for the relief of BPH. Both the French and German governments approve  lipo-philic extracts of saw palmetto berries for this purpose. Saw  palmetto reduces prostate hypertrophy by blocking the conversion of  testosterone to dihydrotestosterone by inhibiting 5-alpha reductase—just like its expensive prescription “cousinâ€�—and by preventing the binding  of DHT to androgen receptor cell sites. These actions increase the  breakdown and excretion of DHT. Saw palmetto also interferes with the  actions of inflammatory substances that contribute to prostate  inflammation and reduces the pro-hypertrophic effects of estrogen and  progesterone on the prostate.

Positive results with saw palmetto  have been confirmed in numerous open as well as double-blind,  placebo-controlled clinical trials. All of these studies  demonstrated statistically significant improvements in the symptoms of  BPH, which included increased volume and rate of urine flow, alleviation of pain and night time urination, and reduced number of voidings per  day. Overall, these studies showed a consistent benefit of saw palmetto  extract, with virtually no side effects of any consequence. A striking  characteristic of these studies is that most subjects experienced relief within days of beginning the therapy, with benefits continuing to  improve over time — in many cases, as much as one year of continuing  improvement! Most studies however, were terminated after 30, 60 or 90  days. A striking characteristic of these studies is that most subjects  experienced relief within days of beginning the therapy, with benefits  continuing to improve over time, in many cases, as much as one year of  continuing improvement!

Most recently, University of Chicago  researchers studied the effects of saw palmetto extract versus placebo  on 85 men, 45 years of age or older.20 The researchers evaluated the  subjects based upon three measurements: the International Prostate  Symptom Score, a sexual function questionnaire, and the urinary flow  rate. At the end of the study, the subjects treated with saw palmetto  experienced significant improvement and reduction of symptoms such as  frequent urination both during the night and day and interruptions in  urination. The researchers stated that their study provides the most  conclusive evidence to date that saw palmetto can benefit men with  prostate problems.

Of particular interest was a study that compared  Proscar with saw palmetto extract that found that saw palmetto had fewer side effects, provided an equivalent or greater benefit, and was a more affordable form of treatment. The optimum dose of saw palmetto in  most clinical studies was 320 mg per day.

Pygeum Africanum

Extracts of the African herb Pygeum africanum have also shown impressive results in relieving symptoms of BPH. The action of pygeum extract in  counteracting prostate hypertrophy is believed to be due to a number of  mechanisms, which include its ability to: (1) inhibit the basic  fibroblast growth factor induced cellular proliferation; (2) inhibit  aromatase; (3) restore secretory activity of the prostatic  epithelium; and (4) increase prostatic secretions.

In one study,  18 patients with BPH or chronic prostatitis, many of whom also had  sexual disturbances, received an extract of pygeum. After 60 days, all  urinary parameters that were investigated were improved, and sexual  disturbances were relieved. In a placebo-controlled French trial of  120 patients, the pygeum group experienced significant reductions in the number of urinations and more complete bladder emptying than the  placebo group.

An international, multi-center, double-blind,  controlled trial of pygeum extract in 263 patients with BPH over a 60  day period showed improved urinary symptoms in 66 percent of the  patients.29 Italian placebo-controlled studies confirmed these  benefits.Most of the clinical studies with pygeum used dosages  ranging from 75-150 mg per day.

Stinging Nettle (Urtica dioica)

Extracts of stinging nettle are used routinely in Europe to treat BPH. Stinging  nettle shares several mechanisms with Pygeum and saw palmetto, but has  several actions that are unique. The known mechanisms of stinging nettle on the prostate include its ability to: (1) inhibit aromatase; (2)  reduce the binding activity of SHBG; (3) inhibit prostate membrane  Na+, K+-ATPase activity; (4) block epidermal growth factor  receptors; and (5) block 5-alpha reductase.
Stinging nettle has  been tested and found to be effective in BPH as a single nutrient,  or in combination with Pygeum. Extracts of stinging nettle when used  alone were superior to placebo, but efficacy was enhanced when combined  with Pygeum. The dosages of stinging nettle in the clinical studies was 300 mg per day.

Beta-Sitosterol

Beta-sitosterol,  one of the main subcomponents of a group of plant sterols known as  phytosterols, is a white, waxy substance with a chemical structure very  similar to that of cholesterol. Research into beta-sitosterol has shown  beneficial effects against a wide variety of human ailments, including  BPH. Beta-sitosterol is the key ingredient in a prescription formulation in Europe, Azuprostat-beta-sitosterol, which has been demonstrated to  improve prostate symptom scores and quality of life, and reduce urine  volume and residual urine levels. The research team reported that “beta-sitosterol itself is an effective option in the treatment of  BPH.”€� Beta-sitosterol was also found to reduce the growth of human  prostate cancer cells.

Conclusion

Beta-sitosterol, and extracts from Saw palmetto, Pygeum africanum, and stinging nettle  have all demonstrated efficacy when used in the treatment and prevention of benign prostatic hypertrophy (BPH). Because of their multiplicity of actions, it should be no surprise that when these phytonutrients are  combined, they are even more effective than when used individually.

References

1. Denis, L.J. Quantification and incidence of benign prostatic hyperplasia. Drugs of Today, 1993, 29-30.
2. Horton R. Benign prostatic hyperplasia: A disorder of androgen metabolism in the male. J Am Geriatr Soc, 1984, 32:380-5.
3. Gormley, G.J., Stoner, E., Bruskewitz, R.C., Imperato-McGinley, J., et  al. The effect of finasteride in men with benign prostatic hyperplasia.  NEJM, 327: 17, 1185-91.
4. Briley, M., Carilla, E., and Fauran, F.  Permixon, a new treatment for benign prostatic hyperplasia, acts  directly at the cytosolic androgen receptor in rat prostate. Brit J  Pharmacol, 1983, 79: 327.
5. Weisser, H., Tunn, S., Behnke, B., and  Krieg, M. Effects of the Sabal serrulata Extract IDS 89 and its  subfractions on 5 alpha reductase activity in human benign prostatic  hyperplasia. The Prostate, 1996, 28: 300-306.
6. Breu, W.,  Hagenlocher, M., Redl, K., et al. Antiphlogistic activity of an extract  from Sabal serrulata fruits prepared by supercritical carbon dioxide/In  vitro inhibition of the cyclooxygenase and 5-lipoxygenase metabolism.  Arzneim-Forsch, 1992, 42 (I):, 4, 547-551.
7. Brown, D.J. Saw palmetto: Herbal prescription for treatment of BPH. Drug Store News for the Pharmacist, 1995, April, 29-30.
8. Tripodi V, Giancaspro M, Pascarella M, et al. Treatment of prostatic  hypertrophy with Serenoa repens extract. Med Praxis, 1983, 4:41-6.
9. Emili E, Lo Cigno M and Petrone U. Clinical trial of a new drug for  treating hypertrophy of the prostate (Permixon). Urologia, 1983,  50:1042-8.
10. Cirillo-Marucco E1, Pagliarulo A, Tritto G, et al:  Extract of Serenoa repens (Permixon) in the early treatment of prostatic hypertrophy. Urologia, 1983, 5:1269-77.
11. Greca P and Volpi R. Experience with a new drug in the medical treatment of prostatic adenoma. Urologia, 1985, 52:532-5.
12. Givia R. Radice GP and Galdini R. Advances m the phytotherapy of prostatic hypertrophy. Med Praxis, 1983, 4:143-8.
13. Crimi A and Russo A. Extract of Serenoa repens for the treatment of the functional disturbances of prostate hypertrophy. Med Praxus, 1983,  4:47-51.
14. Braekman, J. The extract of Serenoa repens in the  treatment of benign prostatic hyperplasia: A multicenter open study.  Current Therapeutic Research, 1994, 55: 7, 776-785.
15. Tasca A,  Barulli M, Cavezzana A, d al: Treatment of obstructive syrnptomatology  caused by prostatic adenoma with an extract of Serenoa repens.  Double-blind clinical study vs. placebo. Minerva Urol Nefrol, 1985,  37:87-91,
16. Champault G. Bonnard AM, Cauquil J and Patel JC:  Medical treatment of prostatic adenoma. Controlled trial: PA 109 vs  placebo in 110 patients. Ann Urol, 1984,18:407-10.
17. Champlault G.  Patel JC and Bonnard AM: A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. Br J Clin Pharmacol,  198418:461-2.
18. Boccafoschi and Annoscia S: Comparison of Serenoa  repent extract with placebo by controlled clinical trial in patients  with prostatic adenomatosis. Urologia, 1983, 50:1257-68.
19. Cukier, P., et al. Permixon versus placebo. Results of a multi-center study. C R Ther Pharmacol Clin, 1985, 4/25: 15-21.
20. Gerber GS, Kuznetsov D, Johnson BC, Burstein JD. Randomized,  double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Urology. 2001 Dec;58(6):960-4; discussion  964-5.
21. Cockett, A.T.K., Khoury, S., Aso, Y., Chatelain, C., et  al. Comparison of phytotherapy (Permixon) with finasteride in the  treatment of benign prostate hyperplasia: A randomized international  study of 1098 patients. Proceedings of the Third International  Consultation on benign prostatic hyperplasia (BPH), Paris: SCI, 1996.
22. Denis, L.J. Editorial review of “Comparison of phytotherapy (Permixon)  with finasteride in the treatment of benign prostate hyperplasia: A  randomized international study of 1098 patients.â€� The Prostate, 1996,  29: 241-242.
23. Bassi , P., et al. Standardized extract of Pygeum  africanum in the treatment of benign orostatic hypertrophy. Controlled  clinical study versus placebo. Minerva Urol Nefrol, 1987, 39 (1): 45-50.
    24. Colpi G. Farina U. Study of the activity of chloroformic extract of  Pygeum africanum bark in the treatment of urethral obstructive syndrome  caused by non-cancerous prostapathy. Urologia, 1976, 43: 441-8.
24. Del Valio B. The use of a new drug in the treatment of chronic prostatitis. Minerva Urol, 1974, 26: 87-94.
25. Paubert-Braquet, M., Monboisse, J.C., Servent-Saez, N., et al.  L’extrait de Pygeum africanum (Tadenantm) inhibie la proliferation des  fibroblastes murins 3T3 par le basic Fibroblast Growth Factor. Biomed  & Pharmacother, 1994, 48, Suppl 1: 435-475.
26. Carani C,  Salvioli V, Scuteri A, et al: Urological and sexual evaluation of  treatment of benign prostatic disease using Pygeum africanum at high  doses. Arch Ital Urol Nefrol Androl , 1991, 63(3): 341-5.
27. Dufour, B., et al. Controlled study of the effects of Pygeum africanum extract  on the functional symptoms of prostatic adenoma. Ann Urol (Paris), 1984, 18(3):193-95.
28. Barlet A, Albrecht, J., Aubert, A., et al.  Efficacy of Pygeum africanum extract in the medical therapy of urination disorders due to benign prostatic hyperplasia: evaluation of objective  and subjective parameters. A placebo controlled double-blind multicenter study. Wien Klin Wochenschr 102(22):667-73, 1990
29. Kraus, R.,  Spiteller, G., Bartsch, W. Octadecadiensaure, ein Aromatase-Hemmstoff  aus dem Wurzelextrakt von Urtica doioica. Liebigs Ann Chem, 1991,  335-339.
30. Gansser, D., Spiteller, G. Aromatase inhibitors from Urtica dioica roots. Z. Naturforsch, 1995, 500: 98-104.
31. Schmidt K: Effect of radix urticae extract and its several secondary  extracts on blood SHBG in benign prostate hyperplasia.] Fortschr Med,  1983, 101 (15): 713-16.
32. Clavert, A., Cranz, C., Riffaud, J.P., et al. Effets d’un extrait d’ecorce de Pygeum africanum (V1326) sue les  secretions prostatiques du rat et de l’homme. Ann Urol, 1986, 20:  341-343.
33. Hirano, T., Homma, M., and Oka, K. Effects of stinging  nettle root extracts and their steroidal components on the Na+,  K+-ATPase of the benign prostatic hyperplasia. Planta Medica, 1994, 60:  30-33.
34. Wagner, H., Geiger, W.N., Boos, G, and Samtleben, R.  Studies on the binding of Urtica dioica agglutinin (UDA) and other  lectins in an in vitro epidermal growth factor receptor test.  Phytomedicine, 1995, 4: 287-290.
35. Belaiche P: Lievoux O. Clinical  studies on the palliative treatment of prostatic adenoma with extract of Urtica root. Phytother Res, 1991, 5:267-9.
36. Romics I. Observations with Bazoton in the management of prostatic hyperplasia. Int Urol Nephrol, 1987, 19(3):293-7.
37. Barsom S. Bettermann AA. Prostatic adenoma: Conservative therapy with  Urtica extract. ZFA (Stuttgart), 1979, 55 (33): 1947-50.
38. Maar K:  Regression of the symptoms of prostatic adenomas. Results of 7 months’  conservative treatment using ERU capsules. Fortschr Med , 1987,  105:18-20
39. Krzeski, T: Kazon, M., Borkowski, A., Witeska, A.,  Kuczera, J. Combined extracts of Urtica dioica and Pygeum africanum in  the treatment of benign prostatic hyperplasia: Double blind comparison  of two doses. Clin Therapeut, 1993, 15: 1012.
40. Klippel K. F., et  al., A multicentric, placebo-controlled, double-blind clinical trial of  beta-sitosterol (phytosterol) for the treatment of benign prostatic  hyperplasia. German BPH-Phyto study group. Br J Urol 1997 Sep; 80(3):  427-32.
41. von Holtz RL, et. Al., beta-Sitosterol activates the  sphingomyelin cycle and induces apoptosis in LNCaP human prostate cancer cells. Nutr Cancer 1998;32(1):8-12.